Type I interferons: key players in normal skin and select cutaneous malignancies

Area of Science:

• Dermatology
• Immunology
• Oncology

Background:

• Interferons (IFNs) are glycoproteins with known antiviral and cell-modulating properties.
• Type I Interferons, specifically IFN-α and IFN-β, are recognized for their therapeutic potential.
• IFN-α is approved for malignant melanoma and used intralesionally for cutaneous SCC and BCC.

Purpose of the Study:

• To review the current understanding of Type I IFN's anti-tumor actions.
• To explore the cellular and molecular mechanisms of IFN-α/β in skin cancers.
• To summarize IFN-α/β's influence on proliferation, apoptosis, angiogenesis, and immune function in normal skin and cutaneous malignancies.

Main Methods:

• Literature review of existing studies on Type I Interferons.
• Analysis of cellular and molecular mechanisms of IFN action.
• Synthesis of data on IFN effects in melanoma, SCC, and BCC.

Main Results:

• IFN-α has demonstrated efficacy in increasing relapse-free survival in melanoma.
• Intralesional IFN-α has shown success in treating SCC and BCC.
• Knowledge gaps exist regarding the precise anti-tumor mechanisms of IFN-α/β in cutaneous malignancies.

Conclusions:

• Type I IFNs possess significant anti-tumor potential in skin cancers.
• Further investigation into the cellular and molecular effects of IFN-α/β is crucial.
• Understanding these mechanisms can optimize therapeutic strategies for melanoma, SCC, and BCC.